The novel use of convalescent plasma in patients with Covid-19 in Basra governorate: Case series review The novel use of convalescent plasma in patients with Covid-19 in Basra governorate: Case series review

Main Article Content

Saad Shaheen Hammadi
Ali Raheem Hashim
Rafid A. Abbood
Abbas Khalaf Ali
Ali Salam Abdullah
Hassanein Mohammed Ali
Ali Radhi Kadhim
Amjed Maya Rodeen
Hiba Jabar Ashoor
Shawqi Abdulsada Aziz
Basim Abdulkareem Abdulhassan
Mustafa Mawih


convalescent plasma, COVID-19, SARS CoV-2, apheresis, plasma exchange, plasma donation


Background: The idea of convalescent plasma usage is to give passive immunity to the patients, so their immune system has a good chance of combating the virus. This study will review 6 cases of eligible Covid-19 patients that had been treated with convalescent plasma therapy in Basra Covid-19 quarantine.


Objectives: to demonstrate efficacy and safety of convalescent plasma  in the patient series that had been  enrolled.


Method:  this study has pioneered a new method to collect up to 3,000 mL of convalescent plasma in one session by an off-label use of Spectra Optia Apheresis systems/TerumoBCT /Exchange set. In this study  250 mL of the collected convalescent plasma had been given to  each of the 6 patients, from one donor. Response in SpO2, dyspnea, and tachypnoea was observed.

Any reaction to plasma also has been monitored .


Result: Our case series have demonstrated both safety and effectiveness of convalescent plasma. This study  was successful in reaching our primary and secondary outcomes in all 6 patients (improvement in SpO2 and symptoms). With negligible difference in time of post transfusion response.


Conclusion: convalescent plasma is apperantly safe and effective. In this study 250 mL of convalescent plasma has been given to each of the 6 patients, from one donor, using Therapeutic Plasma Exchange (TPE) protocol by Spectra Optia Apheresis system/TerumoBCT. 



Abstract 103 |


1) Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb 15;395(10223):497-506.
2) World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 67.
3) World Health Organization. Off-label use of medicines for COVID-19. Scientific Brief. 2020 March 31.
4) Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfusion. 2016 Mar;14(2):152. doi:10.2450/2015.0131-15.
5) Chenguang Shen, Zhaoqin Wang, Fang Zho, Yang Yang, Jinxiu Li, Jing Yuan, Fuxiang Wang, Delin Li, Minghu Yang, Li Xing, Jinli Wei, Haixia Xiao, Yan Yang, Jiuxin Qu, Ling Qing,Li Chen,Zhixiang Xu, Ling Peng, Yanjie Li, Haixia Zheng, Feng Chen, Kun Huang, Yujing Jiang, Dongjing Liu, Zheng Zhang, Yingxia Liu, and Lei Liu. Treatment of 5 Critically Ill Patients WithCOVID-19 With Convalescent plasma, JAMA. doi:10.1001/jama.2020.4783
6) Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020 Apr 28;117(17):9490-6.
7) Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science. 2020 Apr 13;35(14). doi: 10.3346/jkms.2020.35.e149.
8) Lucas SJ, Barry DW, Kind PH. Antibody production and protection against influenza virus in immunodeficient mice. Infection and Immunity. 1978 Apr 1;20(1):115-9.
9) Cooper NR, Nemerow GR. The role of antibody and complement in the control of viral infections. Journal of Investigative Dermatology. 1984 Jul 1;83(s 1):121-7.
10) World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: Interim guidance for national health authorities and blood transfusion services. World Health Organization; 2014.
11) WHO publications 2012 Hospital medical equipment - general information, Apheresis units instruction manual ,p.1
12) Janssens ME, Maru B and De Reys S. Spectra optia® apheresis system therapeutic plasma exchange (TPE), Literature Review. p.5-8.
13) Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly‐Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the seventh special issue. Journal of Clinical Apheresis. 2016 Jun;31(3):149-338. doi: 10.1002/jca.21705
14) Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. Bmj. 2020 Mar 26;368:m1256.
15) Beth Shaz, Cindy Dunbar, and Chris Hillyer. COVID-19 and Convalescent plasma: Frequently Asked Questions. American Society for Haematology, Version 3.0; last updated April 10, 2020

Similar Articles

1-10 of 14

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>